Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects

Amedeo F Capetti, Giuseppe V De Socio, Maria V Cossu, Gaetana Sterrantino, Giovanni Cenderello, Annamaria Cattelan, Gian M Baldin, Alessandro Soria, Niccolò Riccardi, Fosca P Niero, Benedetto M Celesia, Giorgio Barbarini, Stefano Rusconi, Giuliano Rizzardini

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Dolutegravir (DTG) plus boosted darunavir (bDRV) is a compact, adherence-friendly salvage regimen with the highest genetic barrier to HIV-1 resistance. OBJECTIVE: Aim of the present study is to assess the long term (96-week) safety and efficacy of DTG + bDRV in a of multidrug-experienced HIV-1 infected patients, simplifying or building rescue regimens. METHODS: All HIV-1-infected subjects from eleven Italian centers switched to DTG + bDRV between March 2014 and September 2015 were included and followed for minimum 96 weeks. RESULTS: The cohort comprises 130 subjects, switched from 42 different, complex or at least twice-daily regimens, mainly for simplification (44.6%), viral failure (30.0%) or toxicity (16.6%). At baseline 118 had documented resistance to 1-5 antiretroviral classes and 12 lacked genotypic results either for historical reasons or for problems with primer annealing; 52 (40%) had uncontrolled viral replication, three above 500.000 copies/mL. At week 96 two showed ≥50 HIV-1 RNA copies/mL, 23 had 1-49 copies/mL and 101 had no virus detected. The proportion of subjects presenting abnormal values at baseline significantly decreased for serum glucose, creatinine, AST, total cholesterol and triglycerides. CONCLUSIONS: These long-term data confirm the reliability of the two-drug regimen consisting of bDRV plus DTG in salvage settings in HIV-1 infection.
Original languageEnglish
Pages (from-to)242-248
Number of pages7
JournalHIV Clinical Trials
Volume19
Issue number6
DOIs
Publication statusPublished - Dec 2018

Keywords

  • *HIV
  • *darunavir
  • *dolutegravir
  • *dual
  • *salvage
  • *simplification
  • Adult
  • Aged
  • Cohort Studies
  • Darunavir/*therapeutic use
  • Female
  • HIV Infections/*drug therapy/virology
  • HIV Integrase Inhibitors/*therapeutic use
  • HIV Protease Inhibitors/*therapeutic use
  • HIV-1/*drug effects
  • Heterocyclic Compounds, 3-Ring/*therapeutic use
  • Humans
  • Italy
  • Male
  • Middle Aged
  • Reproducibility of Results
  • Salvage Therapy

Fingerprint Dive into the research topics of 'Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects'. Together they form a unique fingerprint.

Cite this